China’s active pharmaceutical intermediate suppliers face tougher documentation scrutiny in 2026

A new review of 10 Chinese active pharmaceutical intermediate suppliers puts documentation, traceability and quality systems ahead of headline capacity. Haohong (Qihe) Pharmaceutical Technology disclosed four utility model patents and an ISO 9001:2015 certificate as buyers increasingly focus on audit-ready evidence.

Why it matters: - Buyers of active pharmaceutical intermediates are screening suppliers more closely on documentation, traceability and regulatory readiness. - The review says headline production capacity matters less than proof of batch control, impurity testing and manufacturing-site traceability. - Haohong (Qihe) Pharmaceutical Technology’s patent disclosures and quality certification highlight the type of evidence buyers now expect before commercial discussions.

What happened: - Haohong (Qihe) Pharmaceutical Technology Co., Ltd. disclosed four utility model patents granted by the China National Intellectual Property Administration. - The company also disclosed ISO 9001:2015 certificate NO:174Q240545R0S, issued by Shandong Guojian Certification Co., Ltd., and valid until 25 November 2027. - The disclosures were released alongside a review of 10 Chinese suppliers of active pharmaceutical intermediates. - The review positions the 10 companies as registered operating entities in China with publicly described activity in pharmaceutical intermediates, APIs or custom synthesis.

The details: - The list includes Haohong (Qihe) Pharmaceutical Technology, Zhejiang Huahai Pharmaceutical, Zhejiang Jiuzhou Pharmaceutical, Asymchem Laboratories, Porton Pharma Solutions, Zhejiang Apeloa Pharmaceutical, Jiangxi Synergy Pharmaceutical, Zhejiang Ausun Pharmaceutical, Shandong Xinhua Pharmaceutical and Zhejiang Hisun Pharmaceutical. - The companies were selected using four publicly checkable criteria: registered corporate status in China, a publicly described product scope, quality management documentation and custom or contract synthesis capability. - The ordering reflects an editorial assessment weighted toward documentation transparency and focus on high-grade intermediates. - The list is not a third-party rating, market-share ranking or claim of product superiority. - Polaris Market Research estimates the global pharmaceutical intermediates market at USD 37.04 billion in 2025. - Mordor Intelligence says bulk drug intermediates accounted for 48.10% of that market by type in 2025. - Mordor Intelligence projects peptide and oligonucleotide intermediates to grow at a 7.85% compound annual rate from 2026 to 2033. - U.S. FDA guidance Q7A requires batch production records for each intermediate and API, plus records that identify failed material and preserve traceability through intermediaries in the supply chain. - European Medicines Agency guidance requires active substances used in marketed medicines to comply with GMP and sets registration obligations for manufacturers and importers of active substances and relevant intermediates. - Haohong says its disclosed portfolio centers on Apalutamide, Abemaciclib and Alectinib intermediates. - Haohong reports a production base in Liaocheng with 30 reactors sized 3,000 to 5,000 litres, annual production capacity of 1,000 tonnes and an R&D team of 30 engineers. - The company reports monthly capacity of 100 metric tonnes and an export share of about 40%, with markets listed as China, the United States, Europe, Japan, India and Bangladesh. - Haohong says its service scope includes structural customization, purity and specification customization, process route customization, capacity and batch customization, packaging and standard customization, and OEM/ODM arrangements. - Haohong says its custom synthesis service runs from gram scale to hundreds of kilograms. - The company lists quality control steps including appearance inspection, chromatographic testing, structural identification, physicochemical testing, heavy metal and impurity testing, microbiological testing and delivery documentation. - The Abemaciclib intermediate list includes 4-Bromo-2,6-difluoroaniline, 5-[(4-Ethylpiperazin-1-yl)methyl]pyridin-2-amine, 2-Bromo-5-formylpyridine, 4-Fluoro-2-methyl-1-isopropyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole and 6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole. - The Alectinib intermediate list includes 2-(4-Ethylphenyl)-2-methylpropanoic acid, 2-(4-Ethyl-3-iodophenyl)-2-methylpropanoic acid and tert-Butyl 6-cyano-2-(2-(4-ethyl-3-iodophenyl)propan-2-yl)-1H-indole-3-carboxylate. - The Apalutamide intermediate list includes 2-Fluoro-4-nitrobenzoic acid, N-Methyl-2-fluoro-4-nitrobenzamide, N-Methyl-2-fluoro-4-aminobenzamide, N-Methyl-2-fluoro-4-bromobenzamide, Methyl 4-bromo-2-fluorobenzoate and 5-Amino-3-(trifluoromethyl)pyridinecarbonitrile. - Published specifications for those listings state purities of 98.0% or higher by HPLC or GC, with storage typically sealed at 2–8 degrees Celsius and protected from light. - The review says Haohong’s patents cover production, analytical and emissions-control equipment rather than compound composition. - Patent 202520639784.6 covers refining and mixing production equipment for pharmaceutical intermediates and is valid to 24 April 2035. - Patent 202521268255.6 covers special production equipment for pharmaceutical intermediates and is valid to 26 May 2035. - Patent 202521280279.3 covers a gas chromatography device for detecting pharmaceutical intermediates and is valid to 27 May 2035. - Patent 202521269185.6 covers production equipment for pharmaceutical intermediates and is valid to 28 May 2035. - The review says ISO 9001:2015 confirms a quality management system audit, not GMP compliance by itself. - The review says no product-level GMP certificate was independently located for any company named.

Between the lines: - The supplier screen is shifting from tonnage and marketing claims toward auditable documentation. - Equipment patents and ISO certification help signal process discipline, but they do not replace product-specific GMP evidence. - The list splits the Chinese market into two models: dedicated intermediate/API producers and CDMOs focused on development-stage projects. - Buyers can misread a CDMO as a catalogue supplier, or vice versa, and that can distort sourcing decisions. - The review suggests more demand will move toward complex chemistry, where analytical capability and regulatory support matter more than output volume.

What's next: - Buyers are being advised to request a certificate of analysis, the batch production record structure, the original manufacturing site identity and address, and any third-party impurity or residual-solvent testing before commercial talks. - Chinese suppliers that can support regulatory filings, document process control and maintain strong analytical capability are likely to stand out in future qualification rounds. - Growth in peptide and oligonucleotide intermediates could push more attention toward higher-complexity chemistry from 2026 to 2033.

The bottom line: - In China’s active pharmaceutical intermediate market, quality evidence is becoming as important as production capacity.